Artificial intelligence company Opyl Ltd (ASX:OPL) is set to form a joint venture with Xco consortium in the United States and United Kingdom to facilitate the marketing, distribution and sale of its products and the services of its product TrialKey, across Europe, the Middle East, Africa and North America. The company – which specialises in utilising AI technologies to elevate clinical trial design and forecast outcomes – has entered into a memorandum of understanding (MOU) with Xco consortium for the formation of the JV in which Opyl will hold a 20% stake. The MOU agreement will be followed …